Physician profile
Christopher J Womack
NPI 1508021312
$824.46
in general payments reported to CMS, 2019-2025
8 companies · $19.64 in 2025
The $19.64 reported for 2025 was less than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $124 · 2022: $171 · 2023: $126 · 2024: $384 · 2025: $19.64.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $530.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $529.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $339.13 | 2020-2024 | |
| Supernus Pharmaceuticals, INC. | $130.10 | 2022-2025 | Qelbree, Qelbree |
| Tris Pharma INC | $119.93 | 2024 | Quillichew Er, Dyanavel Xr, Quillivant |
| Neos Therapeutics, Lp | $101.23 | 2024 | Adzenys Xr-Odt |
| Neurocrine Biosciences, INC. | $48.06 | 2022-2023 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $38.97 | 2022-2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $26.64 | 2022 | |
| Abbvie INC. | $20.40 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Womack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.